BR9607583A - Plasmídio procariótico plasmídio pxl2638 célula procariótica processo de produção de genomas de adenovírus recombinantes processo de preparação de adenovírus recombinantes e composição farmacêutica - Google Patents
Plasmídio procariótico plasmídio pxl2638 célula procariótica processo de produção de genomas de adenovírus recombinantes processo de preparação de adenovírus recombinantes e composição farmacêuticaInfo
- Publication number
- BR9607583A BR9607583A BR9607583A BR9607583A BR9607583A BR 9607583 A BR9607583 A BR 9607583A BR 9607583 A BR9607583 A BR 9607583A BR 9607583 A BR9607583 A BR 9607583A BR 9607583 A BR9607583 A BR 9607583A
- Authority
- BR
- Brazil
- Prior art keywords
- recombinant adenovirus
- plasmid
- prokaryotic
- pharmaceutical composition
- cell production
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 5
- 239000013612 plasmid Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 210000001236 prokaryotic cell Anatomy 0.000 title 1
- 238000010276 construction Methods 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9501632A FR2730504B1 (fr) | 1995-02-13 | 1995-02-13 | Procede de preparation de genomes d'adenovirus recombinants |
| PCT/FR1996/000215 WO1996025506A1 (fr) | 1995-02-13 | 1996-02-09 | Procede de preparation de genome d'adenovirus recombinants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR9607583A true BR9607583A (pt) | 1998-07-07 |
| BR9607583B1 BR9607583B1 (pt) | 2009-12-01 |
| BRPI9607583B8 BRPI9607583B8 (pt) | 2016-11-08 |
Family
ID=9476085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9607583A BRPI9607583B8 (pt) | 1995-02-13 | 1996-02-09 | plasmídios procarióticos recombinantes. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6261807B1 (pt) |
| EP (1) | EP0809704B1 (pt) |
| JP (1) | JP3842818B2 (pt) |
| KR (1) | KR100575521B1 (pt) |
| AT (1) | ATE405662T1 (pt) |
| AU (1) | AU716777B2 (pt) |
| BR (1) | BRPI9607583B8 (pt) |
| CA (1) | CA2210956C (pt) |
| CZ (1) | CZ294338B6 (pt) |
| DE (1) | DE69637648D1 (pt) |
| FI (1) | FI120046B (pt) |
| FR (1) | FR2730504B1 (pt) |
| HU (1) | HU222808B1 (pt) |
| IL (1) | IL117115A (pt) |
| MX (1) | MX9705937A (pt) |
| NO (1) | NO327980B1 (pt) |
| SK (1) | SK286965B6 (pt) |
| WO (1) | WO1996025506A1 (pt) |
| ZA (1) | ZA961153B (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020136708A1 (en) * | 1993-06-24 | 2002-09-26 | Graham Frank L. | System for production of helper dependent adenovirus vectors based on use of endonucleases |
| DE19620687A1 (de) * | 1996-05-22 | 1997-11-27 | Centeon Pharma Gmbh | Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo |
| ATE256196T1 (de) | 1997-06-09 | 2003-12-15 | Genvec Inc | Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten |
| WO1999015686A1 (en) * | 1997-09-23 | 1999-04-01 | Genvec, Inc. | Plasmids for construction of eukaryotic viral vectors |
| CN1342206A (zh) * | 1998-08-28 | 2002-03-27 | 杜克大学 | 在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒 |
| JP2004501602A (ja) * | 1999-02-18 | 2004-01-22 | メルク アンド カンパニー インコーポレイテッド | エンドヌクレアーゼの使用に基づくヘルパー依存アデノウイルスベクターの生産のためのシステム |
| FR2794771B1 (fr) | 1999-06-11 | 2001-08-10 | Aventis Pharma Sa | Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis) |
| FR2799472B1 (fr) | 1999-10-07 | 2004-07-16 | Aventis Pharma Sa | Preparation d'adenovirus recombinants et de banques adenovirales |
| US6998263B2 (en) | 2000-02-09 | 2006-02-14 | Genvec, Inc. | Methods of preparing and using a viral vector library |
| US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| US6573092B1 (en) | 2000-10-10 | 2003-06-03 | Genvec, Inc. | Method of preparing a eukaryotic viral vector |
| AUPR518501A0 (en) | 2001-05-22 | 2001-06-14 | Unisearch Limited | Yin yang-1 |
| EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
| EP1697534B1 (en) | 2003-12-01 | 2010-06-02 | Life Technologies Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
| DK2002003T3 (en) | 2005-05-27 | 2016-03-21 | Ospedale San Raffaele Srl | Gene vector comprising miRNA |
| EP2147105B1 (en) | 2007-05-02 | 2013-04-24 | Merial Limited | Dna plasmids having improved expression and stability |
| US20110269119A1 (en) * | 2009-10-30 | 2011-11-03 | Synthetic Genomics, Inc. | Encoding text into nucleic acid sequences |
| AU2014338864C1 (en) * | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
| US10076562B2 (en) | 2016-04-19 | 2018-09-18 | The Board Of Regents Of The University Of Texas System | Methods for treating plague |
| WO2018054822A1 (en) | 2016-09-20 | 2018-03-29 | Boehringer Ingelheim Vetmedica Gmbh | New swine influenza vaccine |
| NZ751966A (en) | 2016-09-20 | 2023-03-31 | Boehringer Ingelheim Vetmedica Gmbh | New promoters |
| TWI817933B (zh) | 2016-09-20 | 2023-10-11 | 德商百靈佳殷格翰維美迪加股份有限公司 | 新穎ehv***位點orf70 |
| TW201823467A (zh) | 2016-09-20 | 2018-07-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 犬腺病毒載體 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3532566B2 (ja) * | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| SK282843B6 (sk) * | 1993-07-13 | 2002-12-03 | Rhone-Poulenc Rorer S. A. | Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom |
| WO1995003400A1 (en) * | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
| FR2726285B1 (fr) * | 1994-10-28 | 1996-11-29 | Centre Nat Rech Scient | Adenovirus depourvus de particules contaminantes viables, preparation et utilisation |
| DK0787200T3 (da) * | 1994-10-28 | 2005-08-15 | Univ Pennsylvania | Forbedret adenovirus og fremgangsmåder til anvendelse heraf |
| FR2727689A1 (fr) * | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
-
1995
- 1995-02-13 FR FR9501632A patent/FR2730504B1/fr not_active Expired - Lifetime
-
1996
- 1996-02-09 CZ CZ19972554A patent/CZ294338B6/cs not_active IP Right Cessation
- 1996-02-09 WO PCT/FR1996/000215 patent/WO1996025506A1/fr active IP Right Grant
- 1996-02-09 MX MX9705937A patent/MX9705937A/es unknown
- 1996-02-09 DE DE69637648T patent/DE69637648D1/de not_active Expired - Lifetime
- 1996-02-09 AT AT96903077T patent/ATE405662T1/de not_active IP Right Cessation
- 1996-02-09 SK SK1100-97A patent/SK286965B6/sk not_active IP Right Cessation
- 1996-02-09 HU HU9800260A patent/HU222808B1/hu active IP Right Grant
- 1996-02-09 EP EP96903077A patent/EP0809704B1/fr not_active Expired - Lifetime
- 1996-02-09 BR BRPI9607583A patent/BRPI9607583B8/pt active IP Right Grant
- 1996-02-09 KR KR1019970705534A patent/KR100575521B1/ko not_active IP Right Cessation
- 1996-02-09 AU AU47235/96A patent/AU716777B2/en not_active Withdrawn - After Issue
- 1996-02-09 JP JP52470596A patent/JP3842818B2/ja not_active Expired - Lifetime
- 1996-02-09 US US08/894,014 patent/US6261807B1/en not_active Expired - Lifetime
- 1996-02-09 CA CA2210956A patent/CA2210956C/fr not_active Expired - Lifetime
- 1996-02-12 IL IL11711596A patent/IL117115A/xx not_active IP Right Cessation
- 1996-02-13 ZA ZA961153A patent/ZA961153B/xx unknown
-
1997
- 1997-08-08 NO NO19973663A patent/NO327980B1/no not_active IP Right Cessation
- 1997-08-12 FI FI973309A patent/FI120046B/fi not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9607583A (pt) | Plasmídio procariótico plasmídio pxl2638 célula procariótica processo de produção de genomas de adenovírus recombinantes processo de preparação de adenovírus recombinantes e composição farmacêutica | |
| AU7054798A (en) | Modified adenoviral fiber and target adenoviruses | |
| WO1995006743A3 (en) | Methods and compositions for the large scale production of recombinant adeno-associated virus | |
| NO950939L (no) | Defektive adenovirusvektorer og deres anvendelse i gene-terapien | |
| EP1312679B8 (en) | Recombinant MVA virus, and the use thereof | |
| DE69627690D1 (de) | Liposomale formulierungen von mitoxantron | |
| CA2097185A1 (fr) | Vecteurs recombinants viraux pour l'expression dans des cellules musculaires | |
| AU641568B2 (en) | Polypeptide,DNA fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same | |
| EE200000152A (et) | Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon | |
| ATE295853T1 (de) | Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen | |
| EP0437610A4 (en) | Novel physiologically active polypeptide, recombinant plasmid, recombinant microbial cells, medicinal composition, and process for recovering purified polypeptide | |
| ATE424410T1 (de) | Interleukin-19. | |
| AU6144494A (en) | Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases | |
| BR9708227A (pt) | Processo de purificação de dna duplo filamento de pureza farmacêutica preparação de dna plasmídico recombinante e composição farmacêutica | |
| WO1994003601A8 (en) | Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan | |
| NO840952L (no) | Fremgangsmaate til fremstilling av et humant interferon-gamma-polypeptid, rekombinant plasmid omfattende et dna-fragment som koder for peptidet, og mikroorganisme transfermert med plasmidet | |
| DK0769056T3 (da) | Ikke-splejsende verianter af gp350/220 | |
| AU6446190A (en) | Process for inducing analgesia, peptides and therapeutic compositions | |
| AU2438688A (en) | Human t-pa(u-pa) substitution-mutant proteins, recombinant dna coding therefor, transfected host cells, preparation of the mutant proteins, and pharmaceutical compositions | |
| ZA887950B (en) | Human t-pa(u-pa)substitution-mutant proteins,recombinant dna coding therefor,transfected host cells,preparation of the mutant proteins,and pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: AVENTIS PHARMA S.A. (FR) Free format text: ALTERADO DE: RHONE-POULENC RORER S.A. |
|
| B25A | Requested transfer of rights approved |
Owner name: GENCELL S.A. (FR) Free format text: TRANSFERIDO DE: AVENTIS PHARMA S.A. |
|
| B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: GENCELL S.A. (FR) Free format text: A FIM DE ATENDER O SOLICITADO NA PETICAO NO 030274/RJ DE 31/05/2004, QUEIRA APRESENTAR DOCUMENTO DE ALTERACAO DE NOME. |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: GENCELL S.A. (FR) Free format text: REFERENTE A RPI 1858 COD. (25.6) DE 15/08/2006, POR TER SIDO INDEVIDO. |
|
| B25D | Requested change of name of applicant approved |
Owner name: GENCELL SAS (FR) Free format text: ALTERADO DE: GENCELL S.A. |
|
| B25D | Requested change of name of applicant approved |
Owner name: CENTELION (FR) Free format text: ALTERADO DE: GENCELL SAS |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2009, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI-52400.68486/2013 ORIGEM: JUIZO DA 25A VARA FEDERAL DE SAO PAULO PROCESSO NO 0017574-93.2013.4.03.6100 ACAO DE NULIDADE DE PATENTE AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: BAYER SAS, CENTELION E CENTELION S.A., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, MERCK SERONO S.A. E SAMJIN PHARMACEUTICAL CO. LTD. |
|
| B19A | Notification of judicial decision: notification of judicial decision |
Free format text: INPI-52400.068486/2013 SECAO JUDICIARIA DE SAO PAULO - 25A VARA FEDERAL CIVEL DE SAO PAULO PROCESSO NO0017574-93.2013.403.6100 AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: BAYER SAS, CENTELION, CENTELION S.A, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, MERCK SERONO S.A E SAMJIN PHARMACEUTICAL CO. LTDA DECISAO: JULGO PROCEDENTE O PEDIDO FORMULADO PARA DECLARAR A NULIDADE PARCIAL DAS PATENTES PI 9607583-0, PI 9610511-9, PI 9707889-1 E PI 9604907-3 E DETERMINO A RETIFICACAO DOS RESPECTIVOS PRAZOS DE VIGENCIA DE MODO A OBSERVAR A O DISPOSTO NO PARAGRAFO UNICO DO ARTIGO 229 DA LEI NO 9.279-96, EM INTERPRETACAO CONJUNTA COM O CAPUT DO ARTIGO 40 DO MESMO DIPLOMA. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2030 DE 01/12/2009, QUANTO AO PRAZO DE VALIDADE POR DETERMINACAO DA 25A VARA CIVEL FEDERAL DE SAO PAULO, PROC. 0017574-93.2013.403.6100 - ACAO ORDINARIA - INPI 52400.068486/2013-05. |
|
| B19A | Notification of judicial decision: notification of judicial decision |
Free format text: INPI NO 52400.009771/2015-48 PROCESSO JUDICIAL: 0017574-93.2013.4.03.6100 NUP: 00848.000050/2015-10 (REF. 0017574-93.2013.4.03.6100) PARECER DE FORCA EXECUTORIA N. 00012/2020/EEFIN NAP/EEFINSP/PGF/AGU INTERESSADOS: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E OUTROS DECISAO: O JUIZO DA 25A VARA CIVEL FEDERAL DE SAO PAULO JULGOU O PEDIDO PARCIALMENTE PROCEDENTE, PARA DECLARAR A NULIDADE PARCIAL DAS PATENTES PI 9607583-0, PI 9610511-9, E PI 9707889-1, ADEQUANDO AS PATENTES AOS ARTIGOS 229, P. U., E 40, CAPUT, DA LEI N. 9.279-96. ESTA DECISAO FOI POSTERIORMENTE CONFIRMADA PELO TRF DA 3A REGIAO, COM TRANSITO EM JULGADO EM 23 DE JULHO DE 2019. |